Exploratory and population pharmacodynamic analysis of pilot dose-response data in the bioequivalence testing of topical corticosteroid preparations

被引：0

作者：

Endrenyi L. ^{[1
]}

Gao M. ^{[2
]}

Hao Y. ^{[3
]}

机构：

[1] Department of Pharmacology, Department of Preventive Medicine and Biostatistics, University of Toronto

[2] Scian Clinical, Etobicoke

[3] Department of Biostatistics, Ontario Cancer Institute, Princess Margaret Hospital, Toronto

来源：

Drug information journal : DIJ / Drug Information Association | 1997年 / 31卷 / 4期

关键词：

Bioequivalence; Exploratory data analysis; Hill model; Population dynamic analysis; Topical corticosteroids;

D O I：

10.1177/009286159703100421

中图分类号：

学科分类号：

摘要：

A guidance of the Food and Drug Administration (FDA) recommends that the pharmacodynamic (PD) equivalence of topical corticosteroid preparations be demonstrated by a two-step procedure. A pilot study would establish the ED50 of a PD relationship between dose duration and a vasoconstrictor response. The relevance of the assumed hyperbolic Michaelis-Menten response model is evaluated by both graphical exploratory and population PD analyses of the data presented in the guidance. It is shown that the observations are far removed from their asymptotic plateau, and that they can be characterized well by a simplified Hill equation with a Hill coefficient of 0.4. Consequently, it is suggested that pilot studies are not needed when the dose range for sensitive responses is known. Nonresponding subjects should be removed from the analyses of both stages of an investigation. PD equivalence should be assessed with dose durations distanced as far as possible from each other. Finally, the study demonstrates the usefulness of graphical, exploratory analyses without which modeling by regression, including population kinetic and PD computations, can be misinterpreted. © 1997, Drug Information Association. All rights reserved.

引用

页码：1215 / 1226

页数：11

共 13 条

[1] Guidance: topical dermatologic corticosteroids: in vivo bioequivalence, (1995)
[2] Pershing L.K., Lambert L.D., Shah V.P., Lam S.Y., Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans, Int J Pharm, 86, pp. 201-210, (1992)
[3] Pershing L.K., Assessment of topical corticosteroid-induced skin blanching response using the visual McKenzie-Stoughton and colorimetric methods, Drug Inf J, 29, pp. 923-934, (1995)
[4] Pershing L.K., Lambert L.D., Wright E.D., Shah V.P., Williams R.L., Topical 0.05% betamethasone dipropionate: pharmacokinetic and pharmacodynamic dose-response studies in humans, Arch Dermatol, 130, pp. 740-747, (1994)
[5] Smith E.W., Meyer E., Haigh J.M., Maibach H.I., The human skin blanching assay as an indicator of topical corticosteroid bioavailability and potency: an update, Percutaneous Absorption, 2, pp. 443-460, (1989)
[6] Smith E.W., Meyer E., Haigh J.M., Maibach H.I., The human skin blanching assay for comparing topical corticosteroid availability, J Dermatol Treat, 2, pp. 69-72, (1991)
[7] Hauck W.W., Bioequivalence studies of topical preparations: statistical considerations, Int J Dermatol, pp. 29-33, (1992)
[8] Singh G.J.P., Piacquadio D.J., Pershing L.K., Willick K., Lambert L.D., Adams W.P., Schuirmann D.J., Shrivastava S., Shah V.P., Lesko L.J., Williams R.L., Pharmacodynamic (PD) bioequivalence (BE) studies on betamethasone dipropionate cream (DPC). (Abstract), Clin Pharmacol Ther, 59, (1996)
[9] Marston S.A., Rains K., Lane E.A., Population pharmacodynamic modeling of pilot study data to design a pivotal bioequivalence trial for a topical corticosteroid. (Abstract), Pharm Res, 12, pp. S-362, (1995)
[10] Demana P.H., Smith E.W., Walker R.B., Haigh J.M., Kanfer I., Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing, Pharm Res, pp. 303-308, (1997)

← 1 2 →